DAL Outcomes: A phase III double blind, randomized placebo-controlled study, to evaluate the effects of dalcetrapib on cardiovascular (CV) risk in stable CHD patients

ID Number 09-0958

Principal Investigator(s)
Donald A Smith

Department(s) or Division(s)

Research Entity
The Zena and Michael A. Wiener Cardiovascular Institute


The purpose of this study is to find out if a new experimental drug called Dalcetrapib will reduce the risk of death from cardiovascular disease (disease of the heart and blood vessels) or of having a cardiovascular event in people who have had an Acute Coronary Syndrome (symptoms of heart attack)

Contact Information
Ricardo Esquitin
(212) 659-9176

Recruiting Patients: Yes